Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Veradermics, Incorporated
13D/A
Amendment 2
MANE · 922967104
|
8.8% |
8/21/2026
Event 8/19/2026
|
|||
| Montanova Capital, LLC | 8.8% | ||||
| Averill Master Fund, Ltd. | 7.4% | ||||
| Averill Madison Master Fund, Ltd. | 1.5% | ||||
| Aaron Cowen | 8.8% | ||||
|
Abeona Therapeutics Inc.
13G/A
Amendment 2
ABEO · 00289Y206
|
0.9% |
8/14/2026
Event 6/30/2026
|
|||
| Montanova Capital, LLC | 0.9% | ||||
| Aaron Cowen | 0.9% | ||||
|
Kura Oncology, Inc.
13G/A
Amendment 6
KURA · 50127T109
|
9.7% |
8/14/2026
Event 6/30/2026
|
|||
| Montanova Capital, LLC | 9.7% | ||||
| Averill Master Fund, Ltd. | 8.8% | ||||
| Aaron Cowen | 9.7% | ||||
|
Monte Rosa Therapeutics, Inc.
13G/A
Amendment 1
GLUE · 61225M102
|
4.2% |
8/14/2026
Event 6/30/2026
|
|||
| Montanova Capital, LLC | 4.2% | ||||
| Averill Master Fund, Ltd. | 3.8% | ||||
| Aaron Cowen | 4.2% | ||||
|
Fulcrum Therapeutics, Inc.
13G/A
Amendment 2
FULC · 359616109
|
5.5% |
8/14/2026
Event 6/30/2026
|
|||
| Montanova Capital, LLC | 5.5% | ||||
| Averill Master Fund, Ltd. | 3.8% | ||||
| Aaron Cowen | 5.5% | ||||
|
InflaRx N.V.
13G/A
Amendment 2
IFRX · N44821101
|
15.6% |
8/14/2026
Event 6/30/2026
|
|||
| Montanova Capital, LLC | 15.6% | ||||
| Averill Master Fund, Ltd. | 12.5% | ||||
| Aaron Cowen | 15.6% | ||||
|
Replimune Group, Inc.
13G/A
Amendment 1
REPL · 76029N106
|
7.9% |
8/6/2026
Event 7/30/2026
|
|||
| Montanova Capital, LLC | 7.9% | ||||
| Averill Master Fund, Ltd. | 6.7% | ||||
| Aaron Cowen | 7.9% | ||||
|
Faeth Therapeutics, Inc.
13G
FTH · 81728A207
|
7.8% |
6/23/2026
Event 6/15/2026
|
|||
| Suvretta Capital Management, LLC | 7.8% | ||||
| Averill Master Fund, Ltd. | 6.7% | ||||
| Aaron Cowen | 7.8% | ||||
|
Replimune Group, Inc.
13G
REPL · 76029N106
|
5.1% |
5/12/2026
Event 3/31/2026
|
|||
| Suvretta Capital Management, LLC | 5.1% | ||||
| Aaron Cowen | 5.1% | ||||
|
Erasca, Inc.
13G/A
Amendment 1
ERAS · 29479A108
|
1.1% |
5/12/2026
Event 3/31/2026
|
|||
| Suvretta Capital Management, LLC | 1.1% | ||||
| Averill Master Fund, Ltd. | 0.9% | ||||
| Aaron Cowen | 1.1% | ||||
|
Zura Bio Limited
13G/A
Amendment 3
ZURA · G9TY5A101
|
9.9% |
5/12/2026
Event 3/31/2026
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.8% | ||||
| Aaron Cowen | 9.9% | ||||
|
Avalyn Pharma Inc.
13D
AVLN · 05348Y105
|
5.6% |
5/8/2026
Event 5/1/2026
|
|||
| Suvretta Capital Management, LLC | 5.6% | ||||
| Averill Master Fund, Ltd. | 4.9% | ||||
| Averill Madison Master Fund, Ltd. | 0.7% | ||||
| Aaron Cowen | 5.6% | ||||
|
Veradermics, Inc
13D/A
Amendment 1
MANE · 922967104
|
9.9% |
5/5/2026
Event 5/1/2026
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.7% | ||||
| Averill Madison Master Fund, Ltd. | 1.2% | ||||
| Aaron Cowen | 9.9% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
7.7% |
4/13/2026
Event 4/6/2026
|
|||
| Suvretta Capital Management, LLC | 7.7% | ||||
| Averill Master Fund, Ltd. | 6.5% | ||||
| Aaron Cowen | 7.7% | ||||
|
Capricor Therapeutics, Inc.
13G
CAPR · 14070B309
|
6.6% |
2/26/2026
Event 2/19/2026
|
|||
| Suvretta Capital Management, LLC | 6.6% | ||||
| Averill Master Fund, Ltd. | 5.6% | ||||
| Aaron Cowen | 6.6% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 5
STRO · 869367102
|
0% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 0% | ||||
| Averill Master Fund, Ltd. | 0% | ||||
| Aaron Cowen | 0% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 5
STRO · 869367102
|
0% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 0% | ||||
| Averill Master Fund, Ltd. | 0% | ||||
| Aaron Cowen | 0% | ||||
|
Zura Bio Limited
13G/A
Amendment 2
ZURA · G9TY5A101
|
8.6% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 8.6% | ||||
| Averill Master Fund, Ltd | 7.7% | ||||
| Aaron Cowen | 8.6% | ||||
|
Immatics N.V.
13G/A
Amendment 3
IMTX · N44445109
|
8.3% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 8.3% | ||||
| Averill Master Fund, Ltd | 7.1% | ||||
| Aaron Cowen | 8.3% | ||||
|
InflaRx N.V.
13G/A
Amendment 1
IFRX · N44821101
|
11.7% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 11.7% | ||||
| Averill Master Fund, Ltd. | 11.4% | ||||
| Aaron Cowen | 11.7% | ||||
|
Biohaven Ltd.
13G/A
Amendment 3
BHVN · G1110E107
|
7.8% |
2/13/2026
Event 12/31/2025
|
|||
| Suvretta Capital Management, LLC | 7.8% | ||||
| Averill Master Fund, Ltd. | 6.6% | ||||
| Aaron Cowen | 7.8% | ||||
|
Veradermics, Inc
13D
MANE · 922967104
|
11.9% |
2/11/2026
Event 2/5/2026
|
|||
| Suvretta Capital Management, LLC | 11.9% | ||||
| Averill Master Fund, Ltd. | 10.4% | ||||
| Averill Madison Master Fund, Ltd. | 1.5% | ||||
| Aaron Cowen | 11.9% | ||||
|
Palvella Therapeutics, Inc.
13G/A
Amendment 1
PVLA · 697947109
|
7.4% |
11/13/2025
Event 9/30/2025
|
|||
| Suvretta Capital Management, LLC | 7.4% | ||||
| Averill Master Fund, Ltd. | 6.5% | ||||
| Aaron Cowen | 7.4% | ||||
|
89bio, Inc.
13G/A
Amendment 5
ETNB · 282559103
|
5.6% |
11/13/2025
Event 9/30/2025
|
|||
| Suvretta Capital Management, LLC | 5.6% | ||||
| Averill Master Fund, Ltd. | 4.8% | ||||
| Aaron Cowen | 5.6% | ||||
|
Benitec Biopharma Inc.
13D/A
Amendment 4
BNTC · 08205P209
|
44.1% |
11/10/2025
Event 11/7/2025
|
|||
| Suvretta Capital Management, LLC | 44.1% | ||||
| Averill Master Fund, Ltd. | 37.8% | ||||
| Averill Madison Master Fund, Ltd. | 6.3% | ||||
| Aaron Cowen | 44.1% | ||||
|
Compass Therapeutics, Inc.
13G/A
Amendment 1
CMPX · 20454B104
|
8.2% |
8/21/2025
Event 8/13/2025
|
|||
| Suvretta Capital Management, LLC | 8.2% | ||||
| Averill Master Fund, Ltd. | 7.1% | ||||
| Aaron Cowen | 8.2% | ||||
|
PepGen Inc.
13G/A
Amendment 1
PEPG · 713317105
|
0.9% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 0.9% | ||||
| Averill Master Fund, Ltd. | 0.9% | ||||
| Aaron Cowen | 0.9% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 4
STRO · 869367102
|
7.7% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 7.7% | ||||
| Averill Master Fund, Ltd. | 7.7% | ||||
| Aaron Cowen | 7.7% | ||||
|
Immatics N.V.
13G/A
Amendment 2
IMTX · N44445109
|
9.9% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.7% | ||||
| Aaron Cowen | 9.9% | ||||
|
Compass Therapeutics, Inc.
13G
CMPX · 20454B104
|
5.2% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 5.2% | ||||
| Averill Master Fund, Ltd. | 4.5% | ||||
| Aaron Cowen | 5.2% | ||||
|
Erasca, Inc.
13G
ERAS · 29479A108
|
5.1% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 5.1% | ||||
| Averill Master Fund, Ltd. | 4.5% | ||||
| Aaron Cowen | 5.1% | ||||
|
Aura Biosciences, Inc.
13G/A
Amendment 1
AURA · 05153U107
|
7.6% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 7.6% | ||||
| Averill Master Fund, Ltd. | 6.6% | ||||
| Aaron Cowen | 7.6% | ||||
|
Abeona Therapeutics Inc.
13G/A
Amendment 1
ABEO · 00289Y206
|
5.2% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 5.2% | ||||
| Averill Master Fund, Ltd. | 4.5% | ||||
| Aaron Cowen | 5.2% | ||||
|
ArriVent BioPharma, Inc.
13G/A
Amendment 1
AVBP · 04272N102
|
9.9% |
8/13/2025
Event 6/30/2025
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.7% | ||||
| Aaron Cowen | 9.9% | ||||
|
Immatics N.V.
13G/A
Amendment 1
IMTX · N44445109
|
7.5% |
5/2/2025
Event 3/31/2025
|
|||
| Suvretta Capital Management, LLC | 7.5% | ||||
| Averill Master Fund, Ltd. | 6.7% | ||||
| Aaron Cowen | 7.5% | ||||
|
89bio, Inc.
13G/A
Amendment 4
ETNB · 282559103
|
9.9% |
5/2/2025
Event 3/31/2025
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.8% | ||||
| Aaron Cowen | 9.9% | ||||
|
Fulcrum Therapeutics, Inc.
13G/A
Amendment 1
FULC · 359616109
|
9.4% |
5/2/2025
Event 3/31/2025
|
|||
| Suvretta Capital Management, LLC | 9.4% | ||||
| Averill Master Fund, Ltd. | 8.6% | ||||
| Aaron Cowen | 9.4% | ||||
|
Kura Oncology, Inc.
13G/A
Amendment 5
KURA · 50127T109
|
9.4% |
5/2/2025
Event 3/31/2025
|
|||
| Suvretta Capital Management, LLC | 9.4% | ||||
| Averill Master Fund, Ltd. | 8.6% | ||||
| Aaron Cowen | 9.4% | ||||
|
Molecular Partners AG
13G
MOLN · 60853G106
|
10.6% |
5/2/2025
Event 6/15/2021
|
|||
| Suvretta Capital Management, LLC | 10.6% | ||||
| Averill Master Fund, Ltd. | 10.6% | ||||
| Aaron Cowen | 10.6% | ||||
|
Monte Rosa Therapeutics, Inc.
13G
GLUE · 61225M102
|
5.5% |
4/16/2025
Event 4/9/2025
|
|||
| Suvretta Capital Management, LLC | 5.5% | ||||
| Averill Master Fund, Ltd. | 5.1% | ||||
| Aaron Cowen | 5.5% | ||||
|
Aura Biosciences, Inc.
13G
AURA · 05153U107
|
6.1% |
4/11/2025
Event 4/4/2025
|
|||
| Suvretta Capital Management, LLC | 6.1% | ||||
| Averill Master Fund, Ltd. | 5.4% | ||||
| Aaron Cowen | 6.1% | ||||
|
DBV Technologies S.A.
13G
DBVT · 23306J309
|
9.9% |
4/11/2025
Event 4/7/2025
|
|||
| Suvretta Capital Management, LLC | 9.9% | ||||
| Aaron Cowen | 9.9% | ||||
| Averill Master Fund, Ltd. | 8.8% | ||||
|
Benitec Biopharma Inc.
13D/A
Amendment 3
BNTC · 08205P209
|
49.9% |
3/28/2025
Event 3/26/2025
|
|||
| Suvretta Capital Management, LLC | 49.9% | ||||
| Averill Master Fund, Ltd. | 44.5% | ||||
| Averill Madison Master Fund, Ltd. | 5.4% | ||||
| Aaron Cowen | 49.9% | ||||
|
Aadi Bioscience, Inc.
13G
WHWK · 00032Q104
|
10.0% |
3/11/2025
Event 3/4/2025
|
|||
| Suvretta Capital Management, LLC | 10.0% | ||||
| Averill Master Fund, Ltd. | 8.9% | ||||
| Cowen Aaron | 10.0% | ||||
|
Kura Oncology, Inc.
13G/A
Amendment 4
KURA · 50127T109
|
6.7% |
2/13/2025
Event 12/31/2024
|
|||
| Suvretta Capital Management, LLC | 6.7% | ||||
| Averill Master Fund, Ltd. | 5.9% | ||||
| Aaron Cowen | 6.7% | ||||
|
Erasca, Inc.
13G/A
Amendment 1
ERAS · 29479A108
|
4.4% |
2/13/2025
Event 12/31/2024
|
|||
| Suvretta Capital Management, LLC | 4.4% | ||||
| Averill Master Fund, Ltd. | 4.4% | ||||
| Aaron Cowen | 4.4% | ||||
|
89bio, Inc.
13G/A
Amendment 3
ETNB · 282559103
|
8.5% |
2/13/2025
Event 12/31/2024
|
|||
| Suvretta Capital Management, LLC | 8.5% | ||||
| Averill Master Fund, Ltd. | 7.7% | ||||
| Aaron Cowen | 8.5% | ||||
|
Immatics N.V.
13G
IMTX · N44445109
|
6.5% |
2/11/2025
Event 2/4/2025
|
|||
| Suvretta Capital Management, LLC | 6.5% | ||||
| Averill Master Fund, Ltd. | 5.7% | ||||
| Aaron Cowen | 6.5% | ||||
|
Marinus Pharmaceuticals, Inc.
13G
MRNS · 56854Q200
|
5.5% |
2/11/2025
Event 2/7/2025
|
|||
| Suvretta Capital Management, LLC | 5.5% | ||||
| Averill Master Fund, Ltd. | 5.5% | ||||
| Aaron Cowen | 5.5% | ||||
|
Marinus Pharmaceuticals, Inc.
13G/A
Amendment 4
MRNS · 56854Q200
|
3.8% |
2/11/2025
Event 12/31/2024
|
|||
| Suvretta Capital Management, LLC | 3.8% | ||||
| Averill Master Fund, Ltd. | 3.8% | ||||
| Aaron Cowen | 3.8% | ||||
|
PepGen Inc.
13G
PEPG · 713317105
|
5.1% |
2/7/2025
Event 2/5/2025
|
|||
| Suvretta Capital Management, LLC | 5.1% | ||||
| Averill Master Fund, LTD. | 5.1% | ||||
| Aaron Cowen | 5.1% | ||||
|
PepGen Inc.
13G/A
Amendment 1
PEPG · 713317105
|
3.6% |
2/7/2025
Event 12/31/2024
|
|||
| Suvretta Capital Management, LLC | 3.6% | ||||
| Averill Master Fund, Ltd. | 3.6% | ||||
| Aaron Cowen | 3.6% | ||||
|
Fulcrum Therapeutics, Inc.
13G
FULC · 359616109
|
6.3% |
1/6/2025
Event 12/27/2024
|
|||
| Suvretta Capital Management, LLC | 6.3% | ||||
| Averill Master Fund, Ltd. | 5.8% | ||||
| Aaron Cowen | 6.3% | ||||
|
Palvella Therapeutics, Inc.
13G
PVLA · 697947109
|
8.6% |
12/20/2024
Event 12/13/2024
|
|||
| Suvretta Capital Management, LLC | 8.6% | ||||
| Averill Master Fund, Ltd. | 8.6% | ||||
| Aaron Cowen | 8.6% | ||||